These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3109917)

  • 21. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
    Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A
    Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 89Strontium therapy of bone metastases of carcinoma of the prostatic gland.
    Correns HJ; Mebel M; Buchali K; Schnorr D; Seidel C; Mitterlechner E
    Eur J Nucl Med; 1979 Feb; 4(1):33-5. PubMed ID: 499225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Possibilities of systemic radiotherapy with high-purity 89Sr chloride in the treatment of bone metastases].
    Fomin DK; Tararukhina OB; Nazarov AA
    Vestn Rentgenol Radiol; 2012; (2):29-31. PubMed ID: 22730757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?
    Dearnaley DP; Bayly RJ; A'Hern RP; Gadd J; Zivanovic MM; Lewington VJ
    Clin Oncol (R Coll Radiol); 1992 Mar; 4(2):101-7. PubMed ID: 1372817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89.
    Tennvall J; Darte L; Lundgren R; el Hassan AM
    Acta Oncol; 1988; 27(4):365-9. PubMed ID: 2462438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [89Sr Therapy for pain relief in patients with bone metastases].
    Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
    Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic radionuclide therapy in pain palliation.
    Liepe K; Runge R; Kotzerke J
    Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autopsy of a cadaver containing strontium-89-chloride.
    Schraml FV; Parr LF; Ghurani S; Silverman ED
    J Nucl Med; 1997 Mar; 38(3):380-2. PubMed ID: 9074523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.
    Buchali K; Correns HJ; Schuerer M; Schnorr D; Lips H; Sydow K
    Eur J Nucl Med; 1988; 14(7-8):349-51. PubMed ID: 2460352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy.
    Leong C; McKenzie MR; Coupland DB; Gascoyne RD
    J Nucl Med; 1994 Oct; 35(10):1662-4. PubMed ID: 7931669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate.
    Kossman SE; Weiss MA
    Cancer; 2000 Feb; 88(3):620-4. PubMed ID: 10649256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J; Burkert S
    Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89.
    Sciuto R; Maini CL; Tofani A; Fiumara C; Scelsa MG; Broccatelli M
    Nucl Med Commun; 1996 Sep; 17(9):799-804. PubMed ID: 8895908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A direct measurement of strontium-89 activity in bone metastases.
    Ben-Josef E; Maughan RL; Vasan S; Porter AT
    Nucl Med Commun; 1995 Jun; 16(6):452-6. PubMed ID: 7675358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.
    Kraeber-Bodéré F; Campion L; Rousseau C; Bourdin S; Chatal JF; Resche I
    Eur J Nucl Med; 2000 Oct; 27(10):1487-93. PubMed ID: 11083537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.